Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enlivex Therapeutics Ltd 14 Einstein Street Ness Ziona L3 7403618 ISR

www.enlivex.com Employees: 50 P: 972-2620-8072 F: 972-262-0807

Description:

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.

Key Statistics

Overview:

Market Capitalization, $K 26,543
Enterprise Value, $K 25,733
Shares Outstanding, K 21,406
Annual Sales, $ 0 K
Annual Net Income, $ -29,070 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,600 K
EBIT, $ -16,350 K
EBITDA, $ -15,510 K
60-Month Beta 1.01
% of Insider Shareholders 12.28%
% of Institutional Shareholders 1.02%
Float, K 18,777
% Float 87.72%
Short Volume Ratio 0.47

Growth:

1-Year Return -57.88%
3-Year Return -80.32%
5-Year Return -86.33%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -11.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.12 on 11/29/24
Next Earnings Date 12/05/24
Earnings Per Share ttm -0.98
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year 62.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 03/06/19

ENLV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -67.57%
Return-on-Assets % -58.45%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.00
Book Value/Share 1.24
Interest Coverage -1.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar